Human FGFR1 (IIIb) Antibody

FGF R1 alpha Inhibition of FGF acidic-dependent Cell Proliferation and Neutralization by Human FGF R1 Antibody.

Recombinant Human FGF R1a (IIIb) Fc Chimera (Catalog # 655-FR) inhibits Recombinant Human FGF acidic (Catalog # 232-FA) induced proliferation in the NR6R-3T3 mouse fibroblast cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human FGF acidic (0.3 ng/mL) activity elicited by Recombinant Human FGF R1a (IIIb) Fc Chimera (6 ng/mL) is neutralized (green line) by increasing concentrations of Human FGF R1 (IIIb) Monoclonal Antibody (Catalog # MAB765). The ND₅₀ is typically 0.075-0.3 µg/mL in the presence of heparin (10 µg/mL).

Detection of Human FGFR1 by Immunocytochemistry/Immunofluorescence

Proximity between AcSDKP and FGFR1 inhibits the TGF beta/smad signaling pathway in HMVECs. (a) HMVECs were treated with N-FGFR1 (1.5  μg/ml) for 48 h with or without preincubation with AcSDKP (100 nM) for 2 h, and the proximity between AcSDKP and FGFR1 was analyzed by the Duolink In Situ Assay. For each slide, images at a × 400 original magnification were obtained from six different areas. (b and c) HMVECs were treated with TGF beta2 (5 ng/ml) for 15 min or 48 h with or without preincubation with AcSDKP for 2 h, and the p-smad3, TGF betaR1, TGF betaR2 and FGFR1 levels were analyzed by western blot. Densitometric analysis of the p-smad3/smad3, TGF betaR1/ beta-actin, TGF betaR2/ beta-actin and FGFR1/ beta-actin levels from each group (n=6) were analyzed. (d and e) HMVECs were incubated with TGF beta2 for 15 min or 48 h with or without preincubation with AcSDKP or its mutants (AcDSPK, AcSDKA, AcADKP) (100 nM) for 2 h. The p-smad3/smad3, TGF betaR1/ beta-actin, TGF betaR2/ beta-actin and FGFR1/ beta-actin protein levels were analyzed by western blot Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/28771231), licensed under a CC-BY license. Not internally tested by R&D Systems.